SCYX Market Analysis
Wall Street coverage
third-party contextWall Street coverage
$33.55median target· current $4.84 (+593.2%)3 analysts
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
50 articles · sorted by datePage 1 of 3 · 50 total
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeP/E ratio—Forward 3.72
EPS (TTM)$-3.840.0% YoY
Profit margin-120.5%HEALTHCARE
Market cap$384.5MSmall cap
Valuation
- Forward P/E
- 3.72
- PEG ratio
- 0.00
- P/B
- 1.16
- P/S (TTM)
- 2.36
- EV/EBITDA
- 0.05
Profitability & growth
- ROE (TTM)
- -53.4%
- Operating margin
- -120.0%
- Revenue growth YoY
- 1809.0%
- Dividend yield
- —
- Beta
- 1.10
Last earnings
May 11, 2026 · Estimate $-0.99 · Reported $-3.36
Analyst estimate. Actual results often differ.
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Scynexis Inc
Company profileSCYNEXIS, Inc., a biotechnology company, offers therapies for the treatment of yeast infections in the United States. The company is headquartered in Jersey City, New Jersey.
Classification
- Sector
- Healthcare
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 1 EVERTRUST PLAZA, JERSEY CITY, NJ
- Fiscal year end
- December
- Latest quarter
- Mar 31, 2026
Market cap$384.5M
Shares outstanding$79.4M
52W high$10.48
52W low$3.53
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
Balanced Agent